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Abstract Chondromyxoid ﬁbroma (CMF) is a rare
benign primary tumor which usually affects the metaphy-
ses of the long bone of the lower extremities in childhood
and young adults. Rarely, CMF occurs in the skull base and
parasinuses, which may be difﬁcult to distinguish from
chondrosarcoma or chordoma and other tumors in the head.
It is composed of chondroid, myxoid, and ﬁbrous tissue
growth in a lobular pattern, infrequently with calciﬁcations.
We report one case of CMF involving the sphenoid sinus
mimicking a chondrosarcoma. The tumor mass showed
calciﬁcations on images and histology.
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History
A 52-year-old woman presented with vertigo at the ENT
clinic. The patient had no other obvious sinonasal signs or
symptoms, and she had had no other medical or surgical
history in the past. An endonasal examination was per-
formed, and a well-circumscribed, ﬁrm, lobulated sphenoid
mass was encountered.
Radiographic Features
A computerized tomographic scan without contrast was
performed, demonstrating a heterogeneous, partially cal-
ciﬁed a 1.8 9 1.8 9 2 cm mass, located along the intra-
sinus septum and ﬂoor of the sphenoid sinuses. The mass
was well-circumscribed, and partially eroded the ﬂoor of
the sphenoid sinus; it bulged into the sphenoid cavity as
well as protruding slightly into the left nasal cavity
(Fig. 1). Since the lesion contained calciﬁed matrix and
was in the midline, the differential diagnosis included
cartilaginous lesions such as enchondroma and chondro-
sarcoma as well as chordoma. The tumor was removed
endoscopically. The curetted samples consisted of frag-
ments of slightly lobulated, myxochondroid tissue with
ﬁrm areas of calciﬁcation.
Histologic and Immunohistochemical Features
Fragmented tissue sample from the mass was ﬁxed in
neutral formalin and routinely processed for parafﬁn
embedding and stained with hematoxylin and eosin. The
histological morphology revealed a well-circumscribed,
lobulated tumor consisting of myxochondroid matrix in
which the tumor cells were dispersed either in loose and
random aggregates with long cytoplasmic processes dis-
appearing into the tumor matrix, or as spindle cells
resembling ﬁbroblasts. At low magniﬁcation, the tumor
cells were organized into condensed areas of increased
cellularity demarcating pseudolobules of looser areas of
myxochondroid stroma of less cellularity; the tumor
replaced the bone and extended almost into the sphenoid
sinus. In addition, large and small aggregates of amorphous
calciﬁcation in the myxoid stroma corresponded to the
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was seen (Fig. 2a–c). There was no hyaline cartilage dif-
ferentiation anywhere in the tumor matrix. Immunohisto-
chemical stains were positive for vimentin (Fig. 3a) and
smooth muscle actin (Fig. 3b), and negative for S-100
protein, CD34, cytokeratin AE1/AE3 and EMA.
Discussion
Chondromyxoid ﬁbroma (CMF), ﬁrst described in 1948 by
Jaffe and Lichtenstein [1] is an uncommon benign cartilage
congener tumor, which is rare (\1% of primary bone
tumors), which often occurs in children and young adults.
It usually involves the metaphysis of long bones; the most
common site is the proximal tibia [2]. Patients commonly
complain either of pain or a non-tender mass; the duration
of symptoms is highly variable [3, 4]. Only 1–2% of all
cases of Chondromyxoid ﬁbroma reported have occurred in
the head and neck region [5]. It may affect facial bones,
most commonly in mandible and less commonly in the
nasal cavity and paranasal sinuses [6–9]. In the paranasal
sinuses, it has been reported that CMF occurs in the eth-
moid sinus [5, 10] frontal sinus [11, 12] and sphenoid sinus
[7, 11, 13–15] (Table 1). Some authors have described a
female predisposition for intracranial tumors [16, 17]. In
the series of 33 cases reported by Karkuzhali et al. [18], the
Fig. 1 A non-contrast CT scan of the paranasal sinuses showing a
heterogeneous mass with ﬁne calciﬁcations, involving the left
sphenoid sinus. The mass partially eroded the ﬂoor of the sphenoid
sinus and protruded into the left nasal cavity (arrow)
Fig. 2 Low magniﬁcation of tumor mass shows a well circum-
scribed cartilaginous neoplasm, with lobular border and peripheral
hypercellularity (arrowheads)( a). Section shows the tumor (arrow-
heads) is adjacent to the sphenoid cavity lined by sinonasal mucosa
(arrow), with calciﬁcation on the left side (b). High magniﬁcation
shows tumor is composed of chondromyxoid matrix with stellate
ﬁbromyoblastic cells and calciﬁcations (c)
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sphenoid bone, occipital bones, temporal bones and clivus.
The patients were predominantly in their ﬁfth decade of
life.
Chondromyxoid ﬁbromas grossly are well-circum-
scribed, solid, and glistening tan-gray masses showing a
variety of histological features. The typical morphology of
CMF is that of stellate and spindle-shaped cells arranged in
a myxochondroid matrix, characteristically with denser
cellularity at the periphery of loose matrix dividing them
into pseudolobules (Fig. 2a). The neoplastic cells are
spindle-shaped or stellate myoﬁbroblasts, with occasional
multinucleated giant cells seen in the cellular areas. Foci of
calciﬁcation are usually not a prominent feature patho-
logically unless patients are older or the lesions are on or
near the surface of bones (Fig. 2b, c) [19].
Immunohistochemical analysis usually highlights the
immunoreactivity of tumor cells to vimentin (Fig. 3a),
smooth muscle actin (Fig. 3b), Desmin, and sometimes for
S100 protein and CD34. In general, they are negative for
pancytokeratin, EMA and GFAP, and have a low prolif-
erative rate with Ki-67. SOX9, a new marker, has been
reported in the recognition of the chondroid nature of the
CMF and may be useful as an adjunct the diagnosis of
CMF [9].
Calciﬁcations may be noted either radiographically—in
3–16% of cases [3, 20]—or microscopically—in 7–27% of
cases [3, 18, 20, 21]. Yamaguchi and Dorfman [22] have
reported that patients with calciﬁcations tend to be older
(mean age 46 years) than those without calciﬁcations
(21 years), and that calciﬁcations are associated with a
longer duration of symptoms (43.2 months) compared to
tumors without calciﬁcation (6.4 months). Calciﬁcations
therefore appear to be related to the chronicity of the tumor
(and to its location—see above).
Recent, a pericentric inversion of chromosome 6 [inv (6)
(p25q13)] has been proposed as a speciﬁc genetic marker
for CMF of long bone. [23] It has been suggested that
several distinct breakpoints on chromosome 6 are nonran-
domly involved in CMF. The other cytogenetic case report
on a nasal cavity CMF has shown insertion between
chromosome 6 and 19 in a nasal CMF [24].
Wu et al. [11] have evaluated the radiologic appearances
of CMF in a large series. Of 191 cases, 87% had a purely
lucent matrix, and 15% demonstrated some mineralization,
most commonly in the form of calciﬁcations. The
Fig. 3 Immunostains show tumor cells were positive for vimentin
(a) and smooth muscle actin (b)
Table 1 Reported cases of chondromyxoid ﬁbroma of the sphenoid sinus
Cases Age/sex Location Treatment Follow up Authors
1 26/M Petrous-sphenoid bone Complete surgery removal NA Frank et al. [13]
2 66/F Sphenoid sinus Surgery Local recurrence after 1 year;
curetted, 6 months FOD
Nazeer et al. [6]
3 66/F Sphenoid-occipital bone Surgery and radiation Local recurrence after
6 months; after radiation,
20 months FOD
Keel et al. [14]
4 65/F Sphenoid-occipital bone Surgery 26 months FOD Keel et al. [4]
5 NA Sphenoid sinus NA NA Wu et al. [11]
6 44/M Sphenoid sinus Surgery FOD Vernon et al. [15]
NA not applicable, FOD free of disease
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majority had a scalloped, sclerotic rim. Cortical thinning or
expansion, periosteal new bone formation, and poorly
deﬁned margins may also be present. The presence of
calciﬁcations on CT should raise the suspicion of a carti-
laginous or a chondroid matrix-containing lesion. The
typical MRI presentation is with low signal intensity on
T1-weighted images and heterogeneous high signal inten-
sity on T2-weighted images.
CMF is a benign tumor that may be locally aggressive.
The recommended treatment is en bloc excision with a
margin of normal bone. However, curettage is also an
acceptable method in cases of difﬁcult access, or in close
apposition to vital structures. In cases treated with curet-
tage, close surveillance is recommended due to the inci-
dence of recurrence following incomplete resection.
Radiation therapy is generally avoided due to reported
cases of malignant transformation [18, 21].
Appropriate diagnosis of this benign entity is essential
due to its potential misdiagnosis as chondrosarcoma, which
carries a poorer prognosis and may require more radical
surgery [7, 14]. This patient’s CT scan was read as ‘‘sug-
gestive of chondrosarcoma’’—an important differential
diagnosis, particularly in the location of basal skull. In the
head and neck region, chondrosarcoma most commonly
affects the skull base, with rare tumors occurring in other
bones, such as maxilla, mandible and the laryngeal carti-
lages. Radiographically, chondrosarcomas are destructive
lobulated masses that also show calciﬁcations that tend to
be stippled, arc-shaped, or ring-like rather than amorphous.
Morphologically, they are composed of hyaline cartilage,
often with myxoid changes. The chondrocytes are atypical
with enlarged nuclei in which nuclear details are often
visible. The immunophenotype of chondrosarcoma usually
is positive for vimentin and S-100, but it does not express
epithelial markers such as keratin or EMA. Chondrosar-
comas are malignant tumors with 5-year disease-speciﬁc
survival rates in the range of 40–80%. They often require
radical resection to obtain negative margins, and other
methods of tumor therapy have met with little success [25].
The other important differential diagnosis for a tumor
presenting in this location is chordoma, especially the
chondroid variant. Chordoma is a slow-growing malignant
neoplasm arising from ectodermally derived notochordal
remnants and accounts for less than 5% of primary bone
tumors. Morphologically, chordoma is composed of cohe-
sive cells with abundant, bubbly eosinophilic cytoplasm,
known as physaliferous cells. Immunohistochmistry is
useful to distinguish it from CMF. Unlike CMF, chordomas
are positive for S-100 protein, cytokeratin, and EMA.
Chondromesenchymal harmatoma is the other differen-
tial from intranasal cartilaginous tumors. However, this
tumor usually affects children in the ﬁrst few weeks or
months of life. Morphologically, these tumors present
nodules of admixture of various mature cartilage and
myxoid spindle ﬁbrous stroma elements, collagen, and
giant cell rich aneurysmal bone cyst-like features. The
pathogenesis of this tumor is still not well understood.
After this biopsy, this patient’s tumor was determined to
be CMF, permitting total endoscopic resection with a rim
of normal bone.
Although thorough curettage may be able to remove
most of the tumor, a relatively high incidence of recurrence
has been reported due to the inaccessibility the entire tumor
volume to surgery in intracranial anatomical locations.
Since the tumor cannot be completely excised technically,
there is a potential to have local recurrence [21, 26].
In summary, we have presented CMF of the sphenoid
sinus; a rare tumor in a very uncommon location. After
surgery, the patient has remained free of disease for 2 years
with no evidence of local recurrence. Because of some
similarities between CMF and chondrosarcoma on imaging
and morphology, it is important to recognize this rare entity
when it occurs in an unexpected location, allowing the
clinically optimal management and avoiding overtreatment.
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